CEO Alice Zhang Speaks at 2017 Milken Global Conference
CEO Alice Zhang speaks about Verge Genomics on "Young Entrepreneurs Who Are Writing the Biopharma Business Model" panel
May 2, 2017
SAN FRANCISCO — Verge Genomics CEO Alice Zhang was invited to speak on a panel featuring breakthrough biotech entrepreneurs at the famed Milken Global Conference, which draws world leaders, executives, investors, and high-impact individuals annually. At the panel, Zhang discussed her experience co-founding and leading Verge Genomics and both the challenges and the rewards that the biotech industry faces. The panel focused on novel business models, such as Verge's, applying technology solutions to traditional biopharma to improve a field where costs are high and development times long.
The panel was hosted by the FasterCures of the Milken Institute, both of which are non-profit, non-partisan think tanks. FasterCures is a center driven by a singular goal: to save lives by speeding up and improving the medical research system. The Milken Institute aims to increase global prosperity by advancing collaborative solutions that widen access to capital, create jobs and improve health. Their annual global conference brings together leaders with diverse expertise from across sectors and industries for highly focused interactions and compelling content.
About Verge Genomics
Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 12 people including 10 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.